Go to the profile of Teva Pharmaceuticals

Teva Pharmaceuticals

 
  • +1 610 727 3222 or +1-610-786-7158
  • Leaders
  • United States of America
ImmuneMed, Inc. is specialized to diagnose and treat the infectious diseases using antibody and antigen discovery technologies. ImmuneMed Inc. believes that the human immune system itself is the most effective defence system of our body in curing various infectious diseases. These beliefs have been a guiding principle for the company's research over the years. Using the innate immune system, a new antiviral therapeutic has been discovered and developed an endogenous broad-spectrum antiviral drug candidate called Virus suppressing factor (VSF). ImmuneMed has been further developing VSF to humanized VSF (hzVSF) as an immunoglobulin. ImmuneMed has demonstrated the potential of hzVSF in a series of pre-clinical tests including Hepatitis B & C virus and Influenza A virus in vitro and in vivo using several animal models. ImmuneMed did toxicological test for hzVSF and has planned to manufacture GMP drug product of hzVSF in Lonza. Now ImmuneMed expects to enter a phase 1 clinical trial in 2017 in South Korea. In addition, ImmuneMed has been developed the rapid diagnostic kits using lateral flow immunochromatographic assay for early detection of acute febrile illnesses. Now ImmuneMed are developing diagnostic kits including Dengue Haemorrhagic Fever, Typhoid Fever and etc. ImmuneMed has been holding ambitions which contribute to human health to be free from infectious diseases since it was founded in 2000.
NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult to treat, medically unmet bacterial and fungal diseases. The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including Lynovex (in oral and inhaled form), an orphan drug candidate for cystic fibrosis (CF), Novexatin, a potential step change therapy for onychomycosis (being co-developed with and out-licensed to Taro Pharmaceuticals) and Novamycin, a novel antifungal peptide in development for the treatment of aspergillosis, candidiasis and cryptococcosis. Novexatin and Novamycin are among the first-in-class peptide anti-infectives which the company continues to derive from its proprietary antimicrobial peptide rational drug design platform. Lynovex and Nylexa have been developed as novel antimicrobial adjunct therapies from the company's more recently established aminothiol platform. NovaBiotics has a strong portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 with the goal of fully developing and realizing the therapeutic and commercial potential of innate immune system effector based antibacterials and antifungals. NovaBiotics is a privately held company, based in Aberdeen, UK & Raleigh, NC, U.S.
ProMIS Neurosciences, is a TSX listed Company (PMN.TO) headquartered in Toronto, Ontario, with offices in Cambridge MA at the Cambridge Innovation Center. The Company’s mission is to discover and develop precision medicine therapeutics for best in class treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and ALS. ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ & Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, ProMIS is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS. ProMIS has identified five target sites (epitopes) on toxic, misfolded strains of Amyloid beta, a root cause of AD, and created five antibodies specifically addressing these targets (without targeting amyloid beta monomer or plaque, known to be related to poor efficacy and side effects, respectively). ProMIS’ lead antibody product, PMN310, is in late preclinical development, with IND submission anticipated in late 2018. Large pharma companies have invested over $1BB in clinical trials targeting Amyloid beta over the last decade. Significant scientific conclusions can be drawn from results of these trials, indicating that best in class AD antibody therapy should target specifically the toxic, misfolded strains of Amyloid beta and not the other forms. ProMIS’ AD program is specifically designed and is on track to achieve this goal.
Nanowear is a wearable technology platform for medical diagnostics and chronic disease management based on the Company’s proprietary invention of textile-based nanosensors. Nanowear’s flagship product, SimpleSense, is the first-of-its-kind, non-invasive wearable garment for disease management of Congestive Heart Failure. SimpleSense uses these cloth-based, FDA-cleared (Class II) nanosensors to capture multi-channel ECG, Heart-rate variability, Respiratory Rate, Impedance Cardiography (stroke volume / cardiac output), thoracic impedance, actigraphy and cardio-phonography (S3 and S4 detection). Nanowear’s platform algorithmically scores the combination of these metrics for a unique, daily SimpleSense score alerting physicians and caretakers of advanced decompensating heart failure, reducing hospital admissions due to heart failure events. Nanowear’s proprietary sensor technology can also be licensed as a sensor consumable for already-built healthcare products in need of medical-grade sensor technology where exponentially higher signal-to-noise- ratios show capture is unaffected by body hair, moisture, sweat, and motion artifact is significantly reduced.
As the global leader in eye care, Alcon develops and manufactures innovative medicines and devices to serve the full life cycle of eye care needs. Alcon has recently has developed a platform for digitally assisted vitreoretinal surgery (DAVS) that provides a three-dimensional (3D) view of the back of the eye with excellent resolution, image depth of focus, clarity and color contrast.
SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer patients and providers an alternative for the treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy. SetPoint is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the body’s natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human open-label proof-of-concept trial in rheumatoid arthritis in Proceedings of the National Academy of Sciences (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, NEA, Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential Venture Capital Limited and Boston Scientific.
Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
Five Corners is a Sydney based privately owned Australian CRO (Clinical Research Organisation). We provide contract services to manufacturers of medical technologies wishing to perform clinical research in Australia and New Zealand. We collaborate with international CROs, who do not have a presence in Australia or New Zealand, with clinical research services. We also provide Regulatory Consulting Services assisting clients in navigating local regulatory pathways. In addition, our other services include; Field Clinical Engineering, Quality Management System Development, Implementation and Auditing, Manuscript Development, Distributor Profiling, Reimbursement Consulting and Clinical Training. Established over 20 years ago, the clinically specialised team at Five Corners has extensive experience in clinical research and understands the obligations a Local Sponsor has in acting on behalf of an international medical device partner company. Our services are tailored to our clients depending on the current stage of development of the product and the study. Being a boutique clinical research organisation allows flexibility in our approach to meeting the needs of our clients. The Five Corners team is dedicated to providing highly specialised services to our clients within Australia and New Zealand, ensuring that they, and we, undertake activities in line with the ever increasing government and industry standards.
BioMedica Diagnostics is a proudly Canadian company focusing on thrombosis & haemostasis diagnostic solutions for human and animal health. BioMedica offers a comprehensive line of diagnostic and research products recently strengthened through an acquisition of specialty coagulation products and technologies. In the BioMedica line-up, partners will find high quality kits, controls, reagents, calibrators, antibodies and substrates that are designed for clinical use in routine and specialty coagulation and are also widely used in research and industry environments. BioMedica products are available for sale directly to laboratories and can also be purchased worldwide through a network of elite distributors. Many products are Health Canada Registered, FDA 510(k) cleared and/or CE marked. In addition to clinical partners, BioMedica also works with industry partners to OEM or customize products that are manufactured to a partner’s custom requested specifications, available in a final packaged format or as bulk intermediary product, ready for further manufacture.
G-ray Switzerland SA is a development stage company, based in the State of Neuchâtel, Switzerland, with validated core competencies in monolithic CMOS integrated pixel array detector technology. Our mission is to deliver new solutions supporting the development of personal medicine through safer and better X-ray medical imaging. Our first product, the latenium™ detector, will deliver unprecedented price-performance ratio: we aim at establishing latenium™ as an industry-leading product together with established industry actors. The company addresses a large unmet need for low dose X-ray medical applications and brings deep expertise in the areas of: - compounds with ultra-high sensitivity - direct (covalent) bonding technology and the epitaxial growth of defect-free silicon-germanium absorber structures on silicon. We leverage the most recent technologies in material sciences, electronics and medical imaging to innovate and create long-term value for society and shareholders. We want to be a global healthcare technology provider and cultivate an open corporate culture with high ethical standards. We promote innovation, transparency, quality, collaboration, and performance in our interactions with suppliers, partners, the medical community and society. Finally, we also want our core technologies to bring benefits to the industrial sector, in particular in areas contributing to increased compliance and safety.
Icell Kealex Therapeutics is an oncology biotech startup based at JLABS at the Texas Medical Center in Houston, Texas. We are developing oncoloytic vaccinia viruses armed with T-cell-engaging antibody fragments that boost the virus’s antitumor efficacy. This modification in the virus allows the tumor cells that are not infected with the virus to be target by T-cells. Icell Kealex has a deep pipeline of T cell engager oncolytic vaccinia virus which offer an advantage over other oncolytic viruses. We plan to enter phase 1 trials with our lead product in 2018. We are looking for co-development or licensing partnerships
Go to the profile of Luis Lens, MSc.
Luis Lens, MSc.

Clinical trials Analyst at CBIO/NUDFAC-UFPE, CBIO/NUDFAC-UFPE

Go to the profile of Carmen Ramirez
Carmen Ramirez

Sales Account Executive, Springer Nature

ValiSeek Limited was formed as a Joint Venture single asset company in 2014 to progress cancer program VAL401 through early stage clinical trials to a stage attractive for out-licensing. ValiSeek is looking to initiate detailed licensing discussions prior to completion for co-development or out-licensing on a regional, global or disease specific basis to ensure a smooth continuation of their project VAL401.
Aposense, an Israeli publicly-traded biopharmaceutical company (TASE: APOS), is focused on a novel and powerful natural energy resource: the membrane dipole potential, a recently-discovered voltage, measurable in every leaflet of any phospholipid membrane. The dipole potential translates into an enormously strong electric field of up to 1 billion V/m (!), spanning ~30 Å, from membrane surface to membrane center. Excitingly, this electric potential, and its related internal membrane electric field (IMEF) have not been recruited to date for any medical application. Fascinated by the fact that every cell harbors its own discrete and strong powerhouse, Aposense developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities, capable of "energy mining" from the IMEF, and its translation into kinetic energy, for movement within the hydrophobic membrane core. Upon linkage to a cargo drug, this intra-mem¬brane movement of the MNMs can be utilized for energy-consuming tasks, such as enabling the delivery of siRNA into the cytoplasm, where they exert their pharmacological effects, e.g., gene silencing, or moving the drug into drug depot sites generated at the depths of the phospholipid membranes. In both scenarios, Aposense’s MNM are improving pivotal drug features.
TILT Biotherapeutics, founded in 2013, is a leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. The company’s patented technology is used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. TILT has secured almost 10M€ in funding and is now setting up phase I clinical trials, where its approach is further evaluated in cancer patients.
Awaken the body’s Power™ to protect, restore & regenerate Our vision is to “Challenge, Collaborate, Create” to bring innovative, impactful therapies which simplify and increase quality of life. Temple Therapeutics BV is a Dutch domiciled privately held company. We are a clinical stage company focused on developing products that are destined to address unmet medical needs in the hospital’s acute care and surgery departments. Temple’s development focus is on modifying disease. We believe in developing products that unlock the body’s intrinsic capacity to restore balance. Hence, your body is your Temple. Our goal is to develop treatments that truly increase quality of life and ease the financial burden. Our lead asset, Evitar™ has just completed phase I/II trial and is open to partnership opportunities as we enter the pivotal phase across USA, EU and Japan, including other regional markets. FDA meeting completed, regulatory and clinical pathways determined. Currently we are at the beginning stages of our fundraising campaign to complete additional studies including pivotal by 2018.
Go to the profile of R. Kent Clark
R. Kent Clark

Associate Vice President , University of Iowa Foundation